<DOC>
	<DOCNO>NCT00003619</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Isotretinoin may help cancer cell develop normal white blood cell . PURPOSE : Phase I/II trial topotecan , fludarabine , cytarabine , filgrastim follow peripheral stem cell transplantation isotretinoin treat patient acute myeloid leukemia , myelodysplastic syndrome , recurrent refractory acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation Isotretinoin Treating Patients With Acute Myeloid Leukemia , Myelodysplastic Syndrome , Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety topotecan combination fludarabine , cytarabine , filgrastim ( FLAG ) patient poor prognosis acute myeloid leukemia , myelodysplastic syndrome , recurrent refractory acute lymphocytic leukemia . II . Determine maximum tolerate dose topotecan FLAG regimen patient . III . Assess complete remission rate patient treated regimen . OUTLINE : Patients complete response proceed therapy accord age . 65 : Patients receive etoposide IV continuously 5 day , cytarabine IV 2 hour every 12 hour 4 day , filgrastim ( G-CSF ) subcutaneously . Peripheral blood stem cell ( PBSC ) harvest . Patients receive oral busulfan every 6 hour day -7 -4 etoposide IV 10 hour day -3 . PBSC reinfused day 0 . Over 65 : Patients receive oral isotretinoin vitamin E daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow every month 1 year every 3 month thereafter . PROJECTED ACCRUAL : A total 15 patient accrue study within 3-4 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven poor prognosis acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , recurrent/refractory acute lymphocytic leukemia , include : Myelodysplastic syndrome ( MDS ) stag B C Refractory anemia , refractory anemia ring sideroblast , refractory anemia excess blast ( 5 % 20 % myeloblast ) MDS increase erythroblast monocytoblasts great 20 % MDS transformation ( 20 % 30 % myeloblast ) acute nonlymphoblastic leukemia ( least 30 % myeloblast ) Chronic myelomonocytic leukemia Poor prognosis refractory recurrent acute myeloid leukemia complete response Secondary therapy relate AML MDS AML blastic crisis chronic myelogenous leukemia myeloproliferative disorder polycythemia vera , essential thrombocytopenia , agnogenic myeloid metaplasia PATIENT CHARACTERISTICS : Age : 19 90 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT less 2.0 time upper limit normal Renal : Normal serum creatinine Cardiovascular : No congestive heart failure No symptomatic ischemic heart disease Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No uncontrolled infection No poorly control disease ( e.g. , diabetes , systemic lupus erythematosus ) No history psychiatric disorder No malignancy within past 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix No concurrent severe medical problem No history allergic reaction topotecan derivative PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior topotecan At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No investigational drug within 30 day study No concurrent investigational therapy except basal cell skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>thrombocytopenia</keyword>
</DOC>